[go: up one dir, main page]

PL2361250T3 - Nowe polimorficzne formy diwodorofosforanu 6-(1-metylo-1H-pirazolo-4-ylo)-2-{3-[5-(2-morfolino-4-ylo-etoksy)-pirymidyno-2-ylo]-benzylo}2H-pirydazyno-3-onowego oraz sposoby ich otrzymywania - Google Patents

Nowe polimorficzne formy diwodorofosforanu 6-(1-metylo-1H-pirazolo-4-ylo)-2-{3-[5-(2-morfolino-4-ylo-etoksy)-pirymidyno-2-ylo]-benzylo}2H-pirydazyno-3-onowego oraz sposoby ich otrzymywania

Info

Publication number
PL2361250T3
PL2361250T3 PL09756445T PL09756445T PL2361250T3 PL 2361250 T3 PL2361250 T3 PL 2361250T3 PL 09756445 T PL09756445 T PL 09756445T PL 09756445 T PL09756445 T PL 09756445T PL 2361250 T3 PL2361250 T3 PL 2361250T3
Authority
PL
Poland
Prior art keywords
dihydrogenphosphate
pyridazin
morpholin
pyrazol
pyrimidin
Prior art date
Application number
PL09756445T
Other languages
English (en)
Inventor
Axel Becker
Clemens Kuehn
Christoph Saal
Oliver Schadt
Dieter Dorsch
Eva Kriegbaum
Frank Stieber
Cristina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2361250(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2361250T3 publication Critical patent/PL2361250T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL09756445T 2008-12-22 2009-11-24 Nowe polimorficzne formy diwodorofosforanu 6-(1-metylo-1H-pirazolo-4-ylo)-2-{3-[5-(2-morfolino-4-ylo-etoksy)-pirymidyno-2-ylo]-benzylo}2H-pirydazyno-3-onowego oraz sposoby ich otrzymywania PL2361250T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22
EP09756445.4A EP2361250B1 (en) 2008-12-22 2009-11-24 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
PCT/EP2009/008358 WO2010072295A1 (en) 2008-12-22 2009-11-24 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof

Publications (1)

Publication Number Publication Date
PL2361250T3 true PL2361250T3 (pl) 2014-01-31

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09756445T PL2361250T3 (pl) 2008-12-22 2009-11-24 Nowe polimorficzne formy diwodorofosforanu 6-(1-metylo-1H-pirazolo-4-ylo)-2-{3-[5-(2-morfolino-4-ylo-etoksy)-pirymidyno-2-ylo]-benzylo}2H-pirydazyno-3-onowego oraz sposoby ich otrzymywania

Country Status (31)

Country Link
US (1) US8586599B2 (pl)
EP (1) EP2361250B1 (pl)
JP (2) JP5690741B2 (pl)
KR (1) KR101663335B1 (pl)
CN (1) CN102264729B (pl)
AR (1) AR074686A1 (pl)
AU (1) AU2009331990B2 (pl)
BR (1) BRPI0923480B8 (pl)
CA (1) CA2748218C (pl)
CL (1) CL2011001278A1 (pl)
CO (1) CO6331435A2 (pl)
CY (1) CY1114659T1 (pl)
DK (1) DK2361250T3 (pl)
EA (1) EA019320B1 (pl)
EC (1) ECSP11011219A (pl)
ES (1) ES2434247T3 (pl)
HR (1) HRP20130993T1 (pl)
IL (1) IL213647A (pl)
MX (1) MX2011006682A (pl)
MY (1) MY160526A (pl)
NZ (1) NZ594172A (pl)
PE (1) PE20120016A1 (pl)
PL (1) PL2361250T3 (pl)
PT (1) PT2361250E (pl)
SG (1) SG172128A1 (pl)
SI (1) SI2361250T1 (pl)
SM (1) SMT201300133B (pl)
TW (1) TWI448463B (pl)
UA (1) UA103646C2 (pl)
WO (1) WO2010072295A1 (pl)
ZA (1) ZA201105394B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
EP1463509A1 (en) 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
US7250417B2 (en) 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
UA98297C2 (en) 2005-12-21 2012-05-10 Янссен Фармацевтика, Н.В. Triazolopyridazines as tyrosine kinase modulators
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2009050197A2 (en) 2007-10-16 2009-04-23 Novartis Ag Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
MX2010004491A (es) 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
CN101842359A (zh) 2007-10-31 2010-09-22 日产化学工业株式会社 哒嗪酮化合物和p2x7受体抑制剂
EP2220048B1 (en) 2007-11-16 2017-01-25 Boehringer Ingelheim International GmbH Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
WO2009080364A1 (en) 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
JP5411160B2 (ja) 2007-12-21 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス性化合物
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
CA2709650C (en) 2007-12-21 2016-06-07 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
TW200930375A (en) 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2010010150A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US20120028988A1 (en) 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
TWI448463B (zh) 2014-08-11
AU2009331990B2 (en) 2016-04-14
US8586599B2 (en) 2013-11-19
HK1164837A1 (en) 2012-09-28
BRPI0923480B1 (pt) 2020-10-13
IL213647A0 (en) 2011-07-31
BRPI0923480B8 (pt) 2021-05-25
MY160526A (en) 2017-03-15
IL213647A (en) 2013-11-28
HRP20130993T1 (hr) 2013-11-22
JP2012513417A (ja) 2012-06-14
EA201100973A1 (ru) 2012-01-30
SG172128A1 (en) 2011-07-28
BRPI0923480A2 (pt) 2016-08-09
JP5690741B2 (ja) 2015-03-25
WO2010072295A1 (en) 2010-07-01
CY1114659T1 (el) 2016-10-05
KR101663335B1 (ko) 2016-10-06
AR074686A1 (es) 2011-02-02
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11
NZ594172A (en) 2013-04-26
CA2748218A1 (en) 2010-07-01
JP2015028093A (ja) 2015-02-12
JP5860125B2 (ja) 2016-02-16
DK2361250T3 (da) 2013-11-04
PE20120016A1 (es) 2012-01-24
TW201028409A (en) 2010-08-01
SMT201300133B (it) 2014-03-07
AU2009331990A1 (en) 2011-08-11
ECSP11011219A (es) 2011-12-30
CL2011001278A1 (es) 2011-09-30
ZA201105394B (en) 2012-03-28
CO6331435A2 (es) 2011-10-20
CN102264729B (zh) 2014-03-05
EP2361250B1 (en) 2013-08-07
EA019320B1 (ru) 2014-02-28
MX2011006682A (es) 2011-07-13
SI2361250T1 (sl) 2013-12-31
CA2748218C (en) 2017-08-29
US20110257180A1 (en) 2011-10-20
ES2434247T3 (es) 2013-12-16
UA103646C2 (ru) 2013-11-11
CN102264729A (zh) 2011-11-30
EP2361250A1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
SG10201402492TA (en) Use of jak inhibitors 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile
IL207609A0 (en) Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
EP2320904A4 (en) AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
EP2135219A4 (en) SECURE TRANSFER OF ONLINE PRIVILEGES INCLUDING NON-FINANCIAL OPTIONS
MX315904B (es) Inhibidores de fosfoinosituro-3 cinasa.
EG26550A (en) A temperature control device with a disc type that changes the temperature range easily
ZA201105782B (en) Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl}-benzonitrile hydrochloride salt and processes of manufacturing thereof
GB0807612D0 (en) New use of surfactant
ZA201107357B (en) Novel compounds of reverse-turn mimetics, method for manufacturing the same and use therof
EP2222764A4 (en) CONTROL OF THE THICKNESS OF A REMAINING LAYER
PT2231642E (pt) Pirimidinas como inibidores de quinase
EP2311074A4 (en) PROCESS FOR POLISHING NICKEL PHOSPHORUS
EP2242493A4 (en) Gefitinib DERIVATIVES
EP2375954A4 (en) FUSSBODENPOLITURAPPLIKATOR
IL181125A0 (en) Polymorphs of 3-(e)-2-{2-[6-(2-
ZA201105394B (en) Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
HUE037631T2 (hu) A 6-(1H-imidazol-1-il)-2-fenil-kinazolin kristályformái
GB2465180B (en) Method of Contained Transfer
EP2120581A4 (en) METHODS OF IDENTIFYING LYN KINASE ACTIVATORS
IL213198A (en) Preparation for the treatment of primary thrombocythemia
ZA201007178B (en) Inhibitors of jnk
EP2291178A4 (en) PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
EP2288367A4 (en) METHOD FOR PREVENTING PREMATURE DELIVERY
PL2237782T3 (pl) Zastosowanie tetrahydropirymidyn
IL200449A0 (en) Triol form of rosuvastatin